EGFR+ Lung Cancer

BLU-945 Shows Early Antitumor Activity in EGFR-Mutated NSCLC Models

September 20, 2020

In preclinical models of triple-mutated EGFR-positive non–small cell lung cancer, the investigational agent, BLU-945 induced robust antitumor responses, according to results presented at the 2020 European Society of Medical Oncology Virtual Congress.

Clinical Trials Excite Treatment Landscape for Early-Stage EGFR-Mutated NSCLC

September 18, 2020

Balazs Halmos, MD, MS, discusses 2 major presentations from the 2020 American Society of Clinical Oncology Virtual Scientific Program that appeared promising for the treatment of patients with EGFR-mutant non–small cell lung cancer.

Real-World Study Expands Benefit-Risk Assessment Data for Osimertinib in EGFR+ NSCLC

September 03, 2020

The benefits and risks of osimertinib as second- or later-line treatment of patients with EGFR-positive non–small cell lung cancer that were reported when the agent was first approved, have now been confirmed, according to data from a real-world study conducted in Japan.

GioTag Update: Final OS Promising for Sequential Afatinib Following Osimertinib in EGFR+ NSCLC

September 02, 2020

Sequential afatinib followed by osimertinib led to encouraging outcomes in patients with deletion 19 (del19) or L858R epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer, according to the final analysis results from the real-world study, GioTag.

Indications Continue to Expand for EGFR Targeted Therapies in Lung Cancer

August 14, 2020

Research into mutations in the gene encoding the epidermal growth factor receptor protein has revolutionized non–small cell lung cancer treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.

NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy

August 11, 2020

Leora Horn, MD, MSc, discusses the data accrued from Flatiron and from a phase 1/2 trial of patients with refractory non–small cell lung cancer with EGFR exon 20 insertions receiving mobocertinib compared with currently approved therapies.